Security
Moleculin Biotech, Inc. Common Stock · MBRX
MBRXNASDAQCommon stockCurrentCIK 1659617Updated Nov 11, 2026
MBRX price & chart
Loading TradingView…
NASDAQ:MBRX on TradingView ↗About the company
We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 2/3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). We call this the “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation). A blinded preliminary data readout has been released for the MIRACLE trial, we released an interim unblinding of data in June 2026, and we expect an additional unblinding at the end of 2026, thereby concluding Part A of the two-part trial. We believe such early visibility for a pivotal registration-enabling trial is unique in that stakeholders will receive preliminary safety and efficacy data long before the conclusion of the trial.
In the news
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout ↗
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules News provided by Moleculin Biotech, Inc. Feb 25, 2025, 12:35 ET Share this article Share to X Share this article Share to X HOUSTON , Feb. 25, 2025 /PRNewsw ↗
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds News provided by Moleculin Biotech, Inc. Feb 13, 2025, 13:05 ET Share this article Share to X Share this article Share to X HOUSTON , Feb. 13, 2025 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX ) ("Moleculin" or the " ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
4 filing
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 20,353,000Source | 23,394,000Source | 21,087,000Source | 21,593,000Source | 25,575,000Source | 23,363,000Source | 21,013,000Source | 30,845,000Source | 22,126,000Source | 16,925,000Source | 38,217,000Source | 57,422,000Source |
| Property, Plant and Equipment, NetUSD | 77,000Source | 190,000Source | 62,000Source | 99,000Source | 221,000Source | 70,000Source | 127,000Source | 240,000Source | 78,000Source | 159,000Source | 272,000Source | 275,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,703,000Source | 9,405,000Source | 7,262,000Source | 7,557,000Source | 10,845,000Source | 10,317,000Source | 7,716,000Source | 16,824,000Source | 8,878,000Source | 4,278,000Source | 23,550,000Source | 43,145,000Source |
| Assets, CurrentUSD | 7,885,000Source | 11,606,000Source | 8,723,000Source | 9,076,000Source | 13,731,000Source | 10,961,000Source | 9,340,000Source | 18,957,000Source | 9,686,000Source | 5,194,000Source | 26,273,000Source | 45,596,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,182,000Source | 2,201,000Source | 1,461,000Source | 1,519,000Source | 2,886,000Source | 644,000Source | 1,624,000Source | 2,133,000Source | 808,000Source | 916,000Source | 2,723,000Source | 2,451,000Source |
| Operating Lease, Right-of-Use AssetUSD | 343,000Source | 450,000Source | 254,000Source | 370,000Source | 475,000Source | 284,000Source | 398,000Source | 500,000Source | 314,000Source | 424,000Source | 524,000Source | 403,000Source |
| Other Assets, NoncurrentUSD | 900,000Source | — | 900,000Source | 900,000Source | — | 900,000Source | — | — | 900,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 47,273,000Source | 15,915,000Source | 9,500,000Source | 28,758,000Source | 7,870,000Source | 8,180,000Source | 20,971,000Source | 9,258,000Source | 7,120,000Source | 10,946,000Source | 12,144,000Source | 5,231,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 49,000Source | 3,000Source | 7,000Source | 30,000Source | 3,000Source | 5,000Source | 14,000Source | 2,000Source | 3,000Source | 3,000Source | 33,000Source | 29,000Source |
| Retained Earnings (Accumulated Deficit)USD | -221,556,000Source | -151,485,000Source | -226,484,000Source | -167,443,000Source | -140,893,000Source | -218,849,000Source | -159,803,000Source | -136,574,000Source | -206,004,000Source | -153,367,000Source | -131,604,000Source | -101,835,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | -64,000Source | — | — | -52,000Source | — | — | 10,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | -26,920,000Source | 17,411,000Source | 11,587,000Source | -3,585Source | 17,705,000Source | 15,183,000Source | 13,791,000Source | 21,587,000Source | 15,006,000Source | 5,979,000Source | 26,073,000Source | 52,191,000Source |
| Additional Paid in Capital, Common StockUSD | 194,631,000Source | 158,957,000Source | 238,128,000Source | 160,286,000Source | 158,605,000Source | 234,079,000Source | 159,869,000Source | 158,177,000Source | 220,997,000Source | 159,384,000Source | 157,653,000Source | 153,985,000Source |
| Liabilities and EquityUSD | 20,353,000Source | 23,394,000Source | 21,087,000Source | 21,593,000Source | 25,575,000Source | 23,363,000Source | 21,013,000Source | 30,845,000Source | 22,126,000Source | 16,925,000Source | 38,217,000Source | 57,422,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,682,000Source | 5,593,000Source | 9,313,000Source | 7,913,000Source | 5,746,000Source | 7,962,000Source | 6,896,000Source | 5,408,000Source | 6,854,000Source | 5,359,000Source | 6,815,000Source | 4,819,000Source |
| Operating Lease, Liability, CurrentUSD | 132,000Source | 116,000Source | 145,000Source | 128,000Source | 112,000Source | 141,000Source | 124,000Source | 109,000Source | 137,000Source | 120,000Source | — | — |
| Accounts Payable, CurrentUSD | 2,116,000Source | 2,550,000Source | 4,337,000Source | 3,721,000Source | 2,833,000Source | 4,574,000Source | 2,706,000Source | 2,104,000Source | 3,508,000Source | 2,030,000Source | 2,498,000Source | 2,095,000Source |
| Operating Lease, Liability, NoncurrentUSD | 258,000Source | 390,000Source | 147,000Source | 292,000Source | 420,000Source | 185,000Source | 326,000Source | 450,000Source | 222,000Source | 358,000Source | 474,000Source | 335,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,566,000Source | 3,043,000Source | 4,976,000Source | 4,192,000Source | 2,913,000Source | 3,388,000Source | 4,190,000Source | 3,304,000Source | 3,346,000Source | 3,329,000Source | 4,317,000Source | 2,724,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 68,000Source | 92,000Source | 112,000Source | 86,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 21,000Source | 31,000Source | 8,000Source | 29,000Source | 8,000Source | 31,000Source | 90,000Source | 126,000Source | 127,000Source | 130,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 380,000Source | 485,000Source | 1,664,000Source | 1,726,000Source | 1,984,000Source | 2,275,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,067,000Source | 676,000Source | 1,330,000Source | -468,000Source | 403,000Source | 731,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,111,000Source | -4,564,000Source | -22,735,000Source | -23,862,000Source | -24,101,000Source | -27,639,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | -13,000Source | -124,000Source | -67,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | 13,000Source | 124,000Source | 67,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 8,000Source | 26,000Source | 25,000Source | 23,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,612,000Source | 7,999,000Source | 27,284,000Source | 4,635,000Source | 4,651,000Source | -23,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,439,000Source | 3,438,000Source | 4,600,000Source | -19,272,000Source | -19,595,000Source | -27,758,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 6,703,000Source | 9,405,000Source | 7,262,000Source | 7,557,000Source | 10,317,000Source | 7,716,000Source | 8,878,000Source | 4,278,000Source | 23,550,000Source | 43,145,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -62,000Source | 3,000Source | 51,000Source | -32,000Source | -21,000Source | -29,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 303,000Source | 353,000Source | 436,000Source | 417,000Source | 380,000Source | 485,000Source | 1,664,000Source | 1,726,000Source | 1,984,000Source | 2,275,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 100,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,147,000Source | 2,172,000Source | 2,103,000Source | 2,091,000Source | 2,488,000Source | 2,477,000Source | 9,122,000Source | 8,786,000Source | 10,017,000Source | 11,542,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -25,399,000Source | -7,024,000Source | -7,635,000Source | -17,809,000Source | -12,845,000Source | -5,904,000Source | -33,560,000Source | -21,763,000Source | -29,769,000Source | -29,025,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -7,964,000Source | -17,809,000Source | -14,610,000Source | -5,904,000Source | -33,664,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 5,906,000Source | 7,135,000Source | 7,561,000Source | 5,720,000Source | 7,874,000Source | 5,943,000Source | 25,103,000Source | 26,641,000Source | 29,631,000Source | 30,640,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 16,000Source | 9,000Source | 13,000Source | 4,000Source | 76,000Source | 9,000Source | -20,000Source | 43,000Source | 48,000Source | 40,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -5,906,000Source | -7,135,000Source | -7,561,000Source | -5,720,000Source | -7,874,000Source | -5,943,000Source | -25,103,000Source | -26,641,000Source | -29,631,000Source | -30,640,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 16,000Source | 9,000Source | 13,000Source | 4,000Source | 76,000Source | 9,000Source | -20,000Source | 43,000Source | 48,000Source | 40,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -33,560,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -25,399,000Source | -7,024,000Source | -7,635,000Source | -17,809,000Source | -12,845,000Source | -5,904,000Source | -33,560,000Source | -21,763,000Source | -29,769,000Source | -29,025,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.68Source | -1.89Source | -1.4Source | -28.68Source | -3.54Source | -15.8Source | -28.42Source | -6.32Source | -15.07Source | -1.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 37,304,455Source | 3,714,278Source | 5,680,717Source | 621,056Source | 4,124,482Source | 373,751Source | 1,184,569Source | 3,442,997Source | 1,975,610Source | 28,604,397Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 2,147,000Source | 2,172,000Source | 2,103,000Source | 2,091,000Source | 2,488,000Source | 2,477,000Source | 9,122,000Source | 8,786,000Source | 10,017,000Source | 11,542,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | — | -21,763,000Source | -29,769,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -33,496,000Source | — | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | — | 240,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 39,000Source | 102,000Source | -78,000Source | 26,000Source | 34,000Source | 30,000Source | 105,000Source | 550,000Source | 1,368,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -7,964,000Source | -17,809,000Source | -14,610,000Source | -5,904,000Source | -33,664,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 5,906,000Source | 7,135,000Source | 7,561,000Source | 5,720,000Source | 7,874,000Source | 5,943,000Source | 25,103,000Source | 26,641,000Source | 29,631,000Source | 30,640,000Source |
| Research and Development ExpenseUSD | — | — | 3,738,000Source | 4,932,000Source | 5,450,000Source | 3,600,000Source | 5,378,000Source | 3,435,000Source | 15,891,000Source | 17,729,000Source | 19,487,000Source | 18,968,000Source |
Offerings
Registration 333-297776
Registration 333-294686
Registration 333-287727
- Gross proceeds
- 5949600.0
- Net proceeds
- 5533128.0
- Deal price
- 0.37
- Shares
- 16080000
- Offering price
- $0.37
- Ticker
- MBRX